References
- Umanath K , Sika M , Niecestro R , et al. Collaborative Study Group . Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int 2013;17:67-74
- Lewis JB , Sika M , Koury M J, et al, for the Collaborative Study Group. Ferric citrate binds phosphorus and delivers iron to end-stage renal disease patients. J Am Soc Nephrol 2014. [Epub ahead of print]
- Chaknos CM , Berns JS . Erythropoiesis-stimulating agents on trial: are higher dosages causing harm? Am J Kidney Dis 2013;61:6-8
- Fishbane S , Mathew A , Vaziri ND . Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant 2014;29:255-9
- U.S. Renal Data System , USRDS 2013 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2013
- Macdougall IC , Tucker B , Thompson J , et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9
- Fudin R , Jaichenko J , Shostak A , et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305
- Besarab A , Coyne DW . Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010;6:699-710
- Fuller DS , Pisoni RL , Bieber BA , et al. The DOPPS Practice Monitor for US dialysis care: trends through December 2011. Am J Kidney Dis 2013;61:342-6
- Kapoian T , O’Mara NB , Singh AK , et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-9
- Rodby R , Umanath K . Hsieh A, et al, for the Collaborative Study Group: phosphorus binding with ferric citrate reduces erythropoiesis-stimulating agent (ESA) and IV iron usage and cost in patients with ESRD. Am J Kid Dis 2014;63:A95
- Rodby R , Hsieh A . Niecestro R, et al, for the Collaborative Study Group: phosphorus binding with ferric citrate reduces managed care costs through reduced use of iron and erythropoiesis-stimulating agents (ESAs). J Manage Care Pharm 2014;20:S53
- Rooyakers T , Stroes E , Kooistra M , et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002;32(Suppl 1):9-16
- Koulouridis I , Alfayez M , Trikalinos TA , et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56
- Bohlius J , Schmidlin K , Brillant C , et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
- Corwin HL , Gettinger A , Fabian TC , et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76
- Stowell CP , Jones SC , Enny C , et al. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976 2009;34:2479-85